Latest News

Adverum Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043

MENLO PARK, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the completion of dosing
Read More

Clinical Trial for Liver Disease Treatment Imminent After Orphan Drug Designation

Arrowhead Pharmaceuticals Inc. announced last week that the company’s second-generation investigational medicine ARO-AAT was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). ARO-AAT is being developed for the treatment
Read More

UCL’s own News article on our 25,000 donation to them

On the 20th January 2018 we went to UCL to give Professor David Lomas a cheque for £25,000 to go directly to the research of a cure for Alpha-1. You can see our original article here: https://www.alpha1.uk/portfolio/3493. You can see UCL’s news
Read More

First John W. Walsh Translational Research Award Granted

MIAMI and BOSTON, Jan. 31, 2018 /PRNewswire/ — The Alpha-1 Foundation celebrates the first granting of the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency, an honorable award named after John W. Walsh, co-founder of
Read More

Our charity donates £25,000 to the research of a cure

On the 20th January 2018 Alpha-1 Awareness UK went to London to see Professor David Lomas. We were there to make a £25,000 (yes, Twenty Five Thousand pounds) donation to go to the research of a cure for Alpha-1. We were shown around his different lab
Read More

Kamada Reports Collaboration with Hospital Consortium to Evaluate Alpha-1 Antitrypsin …

Kamada Ltd. (NASDAQ: KMDA) today announced a collaboration with the Mount Sinai Acute GvHD International Consortium (MAGIC) to conduct a proof-of-concept clinical trial assessing the safety and preliminary efficacy of Kamada’s Alpha-1-Antitrypsin (AA
Read More